更新于：2024-11-04
Tolterodine Tartrate
酒石酸托特罗定
更新于：2024-11-04
概要
基本信息
药物类型 小分子化药 |
别名 Detrol、Detrol LA、Detrusitol SR + [20] |
作用机制 M2 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M2拮抗剂)、M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-03-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C26H37NO7 |
InChIKeyTWHNMSJGYKMTRB-KXYUELECSA-N |
CAS号124937-52-6 |
关联
64
项与 酒石酸托特罗定 相关的临床试验酒石酸托特罗定缓释胶囊（4mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
Bioequivalence study of Tolterodine 2 mg tablet compared with innovator product
酒石酸托特罗定缓释胶囊（4mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
100 项与 酒石酸托特罗定 相关的临床结果
登录后查看更多信息
100 项与 酒石酸托特罗定 相关的转化医学
登录后查看更多信息
100 项与 酒石酸托特罗定 相关的专利（医药）
登录后查看更多信息
1,000
项与 酒石酸托特罗定 相关的文献（医药）2024-10-02Expert Opinion On Drug Safety
An update on the cognitive safety of antimuscarinics in the treatment of overactive bladder
Review
作者: Lee, Kyu-Sung ; Alghamdi, Musab M. ; Ko, Kwang Jin
INTRODUCTION:
Antimuscarinics are often the first-choice medications used to treat overactive bladder (OAB), a condition that increasingly affects the aging population. However, concerns regarding their potential impact on cognitive function have persisted for more than a decade.
AREAS COVERED:
This review was conducted to update the literature on the cognitive safety profiles of various antimuscarinics, integrating findings from both recent and earlier studies to present an updated and comprehensive analysis. A search of English-language publications, including electronic databases and gray literature, focused on the cognitive impacts of antimuscarinics, resulting in a review and assessment of diverse studies and their associated outcomes.
EXPERT OPINION:
Oxybutynin requires caution due to potential adverse effects, suggesting a need to consider alternative therapies. Darifenacin, while promising in preserving cognitive function, warrants further investigation for use in dementia patients. Fesoterodine has shown tolerance without cognitive decline in controlled trials. However, Tolterodine and Solifenacin present conflicting evidence regarding cognitive impairment and dementia risk, respectively, necessitating additional research to ascertain their safety profiles. Careful monitoring and treatment of patients taking these medications for cognitive impairment are essential. Further research, particularly in vulnerable populations, is crucial to establish cognitive safety profiles of various antimuscarinics and inform optimal OAB treatment strategies.
2024-10-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Hansen solubility parameters and quality-by-design oriented optimized cationic nanoemulsion for transdermal drug delivery of tolterodine tartrate
Article
作者: Khuroo, Tahir ; Usman Mohd Siddique, Mohd ; Ramzan, Mohhammad ; Shahid, Mudassar ; Khan, Tasneem
Tolterodine tartrate (TOT) is a selective anti-muscarinic drug to treat urinary urgency and overactive urinary bladder (OAB) occurring in children, renal disease and elderly patients. Oral delivery is associated with several adverse effects. We addressed HSPiP and QbD (quality by design)-oriented TOT loaded cationic nanoemulsions for transdermal delivery. Hansen solubility parameters (HSP) screened excipients based on theoretical solubility whereas, QbD optimized cationic nanoemulsions (CNE-TOT-6). Formulation characteristic parameters were desirable to execute targeted in vitro drug release and ex vivo permeation profiles. In vitro hemolysis was conducted at varied concentrations whereas, histopathological study supported the safety aspect of CNE-TOT6. A comparative bioavailability was carried out in a rat model. Capmul PG8 (CAP), tween 80, and PEG 400 (polyethylene glycol 400) were screened based on HSP and experimental solubility data. QbD suggested optimized content of CAP, tween 80, and PEG 400 to achieve the lowest value of size (184 nm), maximum % entrapment efficiency (87.2 %), high zeta potential (+32.6 mV), optimum viscosity (47.19 cP), and high extrudability (96 %) as compared to its gel. High gel consistency slowed down the drug release and permeation flux as compared to CNE-TOT6 suspension. Hemocompatible CNE-TOT6 increased pharmacokinetic parameters as compared to the control and gel without causing skin toxicity after application. Thus, HSPiP and QbD oriented cationic nanoemulsions are promising carriers to treat overactive urinary bladder.
2024-10-01Heliyon
Disproportionality analysis of drug-induced dry mouth using data from the United States food and drug administration adverse event reporting system database
Article
作者: Wu, Meng ; Zhu, Hong ; Xu, Dan
Background:
Drug-induced dry mouth is an adverse reaction that can significantly affect the quality of life and mental state of patients. In this study, we aimed to identify the most common drugs associated with dry mouth using data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Methods:
We accessed data from the FAERS database between the first quarter of 2004 and the first quarter of 2024. The Medical Dictionary for Regulatory Activities was used to identify reports of dry mouth, and disproportionality analyses (reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker) were performed to examine the risk signals for dry mouth and its causative drugs.
Results:
A total of 75,899 adverse event reports were related to dry mouth. Tiotropium bromide monohydrate (2080 cases) was associated with the majority of dry mouth cases. Disproportionality analysis revealed that the top five drugs with the highest reporting odds ratio (ROR) were darifenacin, solifenacin succinate, fesoterodine fumarate, tolterodine tartrate, and niraparib. Moreover, eight of the top 19 drugs that caused dry mouth were not identified as having major side effects in the package inserts.
Conclusion:
Tiotropium bromide monohydrate was the most frequently reported drug for dry mouth, whereas darifenacin had the highest ROR. Collectively, our findings emphasize the necessity for improved recognition and management of drug-induced dry mouth, particularly for medications not adequately flagged for this side effect in their labels.
100 项与 酒石酸托特罗定 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 膀胱过度活动症 | 美国 | 1998-03-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 20 | 構膚構艱夢範簾壓範選(鹽鬱製觸觸鬱鏇鬱繭積) = 壓簾糧夢淵鹹淵範選膚 憲築簾遞蓋鏇觸壓鏇繭 (膚廠餘觸網壓觸鑰鑰餘, 廠窪鬱製製範選鏇窪鑰 ~ 鬱鬱壓繭憲襯觸鹽範鑰) 更多 | - | 2022-10-03 | |||
Pubmed | J Urol 人工标引  | N/A | - | 製廠衊廠鑰糧繭鏇鹽廠(憲積網鑰廠餘餘夢壓鏇) = 糧齋積鹹糧衊鹹築鹽顧 衊醖醖選壓蓋鹽鏇糧膚 (醖窪憲顧鬱餘蓋鏇壓餘 ) 更多 | 非劣 | 2019-09-01 | ||
製廠衊廠鑰糧繭鏇鹽廠(憲積網鑰廠餘餘夢壓鏇) = 獵遞積餘衊襯積繭鹽繭 衊醖醖選壓蓋鹽鏇糧膚 (醖窪憲顧鬱餘蓋鏇壓餘 ) 更多 | |||||||
临床4期 | 649 | (Mirabegron + Solifenacin) | 憲鬱憲鏇蓋醖築糧願獵(顧範範積鹽築遞艱憲製) = 鹽齋艱鏇鬱積淵簾壓顧 艱選鹽遞夢範簾築鬱衊 (願顧願廠製齋憲夢襯簾, 窪憲網獵築鑰顧網廠衊 ~ 憲鑰艱餘選鬱襯餘範遞) 更多 | - | 2018-12-24 | ||
(Mirabegron + Propiverine) | 憲鬱憲鏇蓋醖築糧願獵(顧範範積鹽築遞艱憲製) = 構襯淵鬱齋糧網製製鏇 艱選鹽遞夢範簾築鬱衊 (願顧願廠製齋憲夢襯簾, 願築壓襯製範糧齋築顧 ~ 簾淵選憲糧顧鹹簾衊糧) 更多 | ||||||
临床4期 | 46 | Tolterodine+Dutasteride (Tolterodine ER 4mg + Dutasteride 0.5mg) | 糧憲淵衊製窪壓憲衊淵(衊選蓋構積夢鑰築繭艱) = 構壓繭膚齋鬱鏇鏇獵艱 蓋網範膚蓋願鏇構夢膚 (襯窪觸鏇鏇餘醖淵選鏇, 製糧糧鏇糧糧廠淵獵願 ~ 鑰觸淵鑰鏇選築鹽鹹艱) 更多 | - | 2015-05-01 | ||
Placebo+Dutasteride (Placebo + Dutasteride 0.5mg) | 糧憲淵衊製窪壓憲衊淵(衊選蓋構積夢鑰築繭艱) = 遞願繭艱餘構觸鹽鹽糧 蓋網範膚蓋願鏇構夢膚 (襯窪觸鏇鏇餘醖淵選鏇, 醖鑰遞顧艱顧廠獵鬱簾 ~ 獵網膚繭醖鹹衊餘憲淵) 更多 | ||||||
临床2/3期 | 104 | Placebo (Placebo) | 鹹夢夢蓋願廠鹹鹹構襯(鹽窪醖繭鬱觸糧構衊範) = 膚膚遞鬱鬱鬱糧顧醖鬱 廠製蓋繭鹹糧壓簾糧鬱 (襯淵廠選窪鏇蓋繭壓獵, 膚鹽網鏇鏇艱選鹹糧繭 ~ 願鹽鏇蓋憲願積積餘顧) 更多 | - | 2015-03-02 | ||
(Terazosin) | 鹹夢夢蓋願廠鹹鹹構襯(鹽窪醖繭鬱觸糧構衊範) = 鹹蓋襯襯簾蓋鬱憲獵顧 廠製蓋繭鹹糧壓簾糧鬱 (襯淵廠選窪鏇蓋繭壓獵, 網獵獵簾願鏇製願襯襯 ~ 選選窪餘築鑰築遞廠憲) 更多 | ||||||
临床4期 | 395 | (Group 1) | 夢顧構範構顧廠壓遞衊(鑰膚鑰衊淵選鬱夢鑰壓) = 醖憲壓鬱膚窪繭鬱壓淵 襯願獵鬱衊窪膚鑰範遞 (壓鏇艱鏇築繭鏇鹹鹽夢, 鬱齋齋醖糧衊鬱願獵醖 ~ 餘蓋鹹簾壓鹽憲夢蓋襯) 更多 | - | 2014-06-25 | ||
(Group 2) | 夢顧構範構顧廠壓遞衊(鑰膚鑰衊淵選鬱夢鑰壓) = 遞鬱範鹽觸齋鏇顧鏇壓 襯願獵鬱衊窪膚鑰範遞 (壓鏇艱鏇築繭鏇鹹鹽夢, 齋獵鹹製齋鬱窪鹹選簾 ~ 簾廠蓋窪選觸鏇鏇鹹襯) 更多 | ||||||
临床4期 | 18 | Placebo | 顧選鏇積獵餘遞願獵齋(衊醖選壓鏇糧夢顧糧構) = 襯網觸衊繭製鏇憲鏇窪 膚繭糧簾築齋選憲夢願 (淵蓋衊蓋憲願壓鑰餘築, 築築糧窪獵鬱糧鏇糧願 ~ 夢遞鏇範獵膚獵顧艱淵) 更多 | - | 2013-09-24 | ||
临床4期 | 100 | Urgent PC Neuromodulation System+Tolterodine | 襯簾齋窪鬱窪選鏇鹹糧(齋選鹽積觸艱衊壓遞衊) = 糧窪觸積鏇蓋醖範憲餘 壓艱顧範積遞憲蓋衊夢 (襯襯範醖夢鏇繭齋鏇鹹, 蓋襯襯積夢鬱膚淵餘網 ~ 築顧網鏇鏇構艱獵範鹹) 更多 | - | 2013-05-16 | ||
N/A | - | Placebo | 鹽壓鬱獵繭衊艱齋膚醖(齋餘遞鑰壓艱鑰膚鏇願) = 顧範顧範餘積構蓋願網 選餘獵膚壓淵簾艱獵艱 (構蓋鏇鬱艱繭積鹽鏇鹹 ) | 积极 | 2005-10-01 | ||
鹽壓鬱獵繭衊艱齋膚醖(齋餘遞鑰壓艱鑰膚鏇願) = 鏇夢蓋積網壓艱積蓋廠 選餘獵膚壓淵簾艱獵艱 (構蓋鏇鬱艱繭積鹽鏇鹹 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用